Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Utah.
Press releases published on August 6, 2025
GetSetUp Athletes Triumph at the National Senior Games
EIN Presswire
·
August 6, 2025
GetSetUp celebrates its inspiring athlete community at the 2025 National Senior Games, sharing stories of courage and perseverance that transcend medals. MIDVALE, UT, UNITED STATES, August 6, 2025 /EINPresswire.com/ -- GetSetUp, the largest learning and …
AllenComm Named as a Top eLearning Company For Simulation Training 2025 by eLearning Industry
EIN Presswire
·
August 6, 2025
SALT LAKE CITY, UT, UNITED STATES, August 6, 2025 /EINPresswire.com/ -- The award-winning team at AllenComm, a full-service learning and development (L…
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 6, 2025
MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from …
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
·
August 6, 2025
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 …
STERIS Announces Chief Financial Officer Transition
GlobeNewswire
·
August 6, 2025
Long-time CFO Michael J. Tokich to be succeeded by Karen L. Burton, Chief Accounting Officer DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that Michael J. Tokich, Senior Vice …
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
GlobeNewswire
·
August 6, 2025
Safety Review Committee endorses escalation to 160 mg TUS dosing Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs) in some of the most difficult-to-treat AML populations …
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 6, 2025
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules Strengthened discovery …
Surrozen to Present at Upcoming Healthcare Investor Conference
GlobeNewswire
·
August 6, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and …
STERIS Announces Financial Results for Fiscal 2026 First Quarter
GlobeNewswire
·
August 6, 2025
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34 Fiscal 2026 revenue and free cash flow outlook updated DUBLIN, …
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated …
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trial Enrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through Week 12 on track for Q4 2025 Ongoing …
DLH Reports Fiscal 2025 Third Quarter Results
GlobeNewswire
·
August 6, 2025
ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to …
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
GlobeNewswire
·
August 6, 2025
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. …
Certara Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 …
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 million Second Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior year Second Quarter 2025 …
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
GlobeNewswire
·
August 6, 2025
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year …
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
GlobeNewswire
·
August 6, 2025
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) …
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
GlobeNewswire
·
August 6, 2025
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, …
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a …
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
GlobeNewswire
·
August 6, 2025
First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with …